Home › Trial NCT05713110
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
- Trial IDNCT05713110
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorHutchmed
- Enrollment61
- Start date2023-02-13
- ConditionsRelapsed/Refractory Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.